OPRD1
Delta-type opioid receptor
Protein Summary
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.
- ENST00000234961
- ENSP00000234961
- ENSG00000116329
- OPRD
- DOP
- DOR
- DOR1
- OPRD
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
drug | 0.98 | ||
ligand (chemical) | 0.98 | ||
biological process | 0.89 | ||
gene perturbation | 0.76 | ||
chemical | 0.75 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 174.18 (req: < 5)
Gene RIFs: 85 (req: <= 3)
Antibodies: 380 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 174.18 (req: >= 5)
Gene RIFs: 85 (req: > 3)
Antibodies: 380 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 26
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 2139
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 16